This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
08/04/15 - 3:59:55 PM ET (BATS BZX Real-time Price)
Div Yield: --
GERN Day's Range
GERN 52 Week Range
GERN Business Summary
Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc.View GERN key stats
Geron Corp - GERN - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Geron Corp as a
Sell with a ratings score of D-.
Report Snippet: We rate GERON CORP (GERN) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and disappointing return on equity.